Lung Cancer

Ventura, CA

157 Lung Cancer Trials near Ventura, CA

Power is an online platform that helps thousands of Lung Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

AZD8205 for Endometrial Cancer

Santa Monica, California
This trial is testing a new drug called AZD8205 to see if it can help treat advanced or spreading solid tumors. The study includes patients whose cancer is advanced or has spread and may not respond to current treatments. AZD8205 might work by stopping or slowing down the growth of cancer cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

370 Participants Needed

Combination Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

Los Angeles, California
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

630 Participants Needed

Patritumab Deruxtecan for Non-Small Cell Lung Cancer

West Hollywood, California
This trial is testing a new drug called patritumab deruxtecan for patients with advanced lung cancer who have specific genetic mutations and have not responded to other treatments. The drug targets cancer cells specifically and delivers chemotherapy directly to them.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

277 Participants Needed

DS-1062a for Lung Cancer

Santa Monica, California
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

137 Participants Needed

Combination Therapy for Lung Cancer

Los Angeles, California
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

99 Participants Needed

Talazoparib + Temozolomide for Small Cell Lung Cancer

Los Angeles, California
This trial studies how effective talazoparib and temozolomide are for treating patients with extensive-stage small cell lung cancer that has come back after initial chemotherapy. Talazoparib stops cancer cells from repairing their DNA, while temozolomide kills or stops the growth of these cells. The combination may work better than either drug alone.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

35 Participants Needed

Telisotuzumab Vedotin for Lung Cancer

Los Angeles, California
This trial tests telisotuzumab vedotin, a treatment that targets and kills cancer cells, in NSCLC patients with high c-Met levels. It aims to find the best patient group for this therapy and evaluate its safety and effectiveness. Telisotuzumab vedotin is a specialized treatment targeting c-Met-overexpressing tumor cells, and it has been evaluated in various studies for its safety and efficacy in treating advanced solid tumors, including non-small cell lung cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

270 Participants Needed

Veliparib + Chemoradiation for Advanced Non-Small Cell Lung Cancer

Beverly Hills, California
This phase I/II partially randomized trial studies the side effects and best dose of veliparib when given together with radiation therapy, carboplatin, and paclitaxel and to see how well it works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether radiation therapy, carboplatin, and paclitaxel are more effective with or without veliparib in treating non-small cell lung cancer.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

53 Participants Needed

TAK-788 for Non-Small Cell Lung Cancer

Los Angeles, California
This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment. Non-Asian, non-White participants will take TAK-788 to determine the safety and tolerability of TAK-788 treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

334 Participants Needed

NT-112 for Solid Tumors

Los Angeles, California
This trial tests NT-112, a personalized immune cell treatment, in patients with advanced cancers that have a specific genetic mutation. The treatment boosts the patient's immune cells to target and kill cancer cells. This highly personalized cancer therapy involves giving the patient immune cells that directly attack cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

24 Participants Needed

Immunotherapy + Radiotherapy for Non-Small Cell Lung Cancer

Beverly Hills, California
This trial is testing a new treatment for advanced lung cancer using special immune cells from healthy donors and a small amount of radiation. The goal is to see if this combination is safe and effective. The immune cells help the body fight cancer, and the radiation makes the cancer cells easier to attack.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

48 Participants Needed

Osimertinib + Carotuximab for Lung Cancer

Los Angeles, California
The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

60 Participants Needed

Dendritic Cell Vaccine + Pembrolizumab for Lung Cancer

Los Angeles, California
This trial tests a special vaccine made from the patient's own cells and a virus, combined with a drug that boosts the immune system, in patients with advanced lung cancer who have already tried other treatments. The vaccine helps the immune system recognize cancer, and the drug helps the immune system attack it.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

24 Participants Needed

CPO301 for Cancer

Santa Monica, California
This trial tests CPO301, a drug that targets and kills cancer cells, in adults with advanced or metastatic solid tumors who have limited treatment options. The drug uses an antibody to find cancer cells and deliver chemotherapy directly to them.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

102 Participants Needed

RO7496353 Combination Therapy for Metastatic Cancer

Los Angeles, California
The purpose of this study is to evaluate the safety and tolerability of RO7496353 in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or metastatic solid tumors such as non-small cell lung cancer (NSCLC), gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). The substudy will evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor activity of RO7496353 in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC). The parent and substudy will be conducted in 2 stages: an initial safety run-in stage and an expansion stage.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

102 Participants Needed

TILT-123 + Pembrolizumab for Lung Cancer

Santa Monica, California
This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

22 Participants Needed

Mindful Self-Compassion for Lung Cancer

Los Angeles, California
The goal of this pilot clinical trial is to test a disease-tailored, mindfulness-based intervention (Mindful Self-Compassion for Lung Cancer; MSC-LC) in adults diagnosed with lung cancer who are experiencing stigma. The current project seeks to: * Evaluate preliminary evidence for the feasibility, acceptability, and preliminary efficacy of MSC-LC in reducing stigma for adults with lung cancer, compared to a waitlist control condition * Elicit interventional impact not captured through quantitative measures with qualitative data from purposively sampled high responders and non-responders from the intervention condition Participants will randomized to either the MSC-LC intervention (a 10-week, virtually-delivered, group-based psychosocial intervention focused on the development of mindfulness and self-compassion skills) or to a waitlist control group that receives a referral to an NCI list of helpful mental health resources in their community. Researchers will compare the intervention and control groups to see if the MSC-LC intervention reduces lung cancer stigma and increases self-compassion.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

60 Participants Needed

Surgery vs Stereotactic Radiotherapy for Lung Cancer

West Los Angeles, California
Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation. However, an alternative treatment known as stereotactic radiotherapy now appears to offer an equally effective alternative. Doctors believe both are good treatments and are therefore conducting this study to determine if one may be possibly better than the other.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

670 Participants Needed

Blood Test for Lung Cancer

Los Angeles, California
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:50+

20000 Participants Needed

H002 for Non-Small Cell Lung Cancer

Los Angeles, California
This is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in patients with active EGFR mutation locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will contain two parts: Part A is dose escalation phase (i.e., Phase I) and Part B is dose expansion phase (i.e., Phase IIa).
No Placebo Group

Trial Details

Trial Status:Recruiting

76 Participants Needed

Why Other Patients Applied

"I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

EQ
Lung Cancer PatientAge: 70

"My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

OF
Cholangiocarcinoma PatientAge: 54

"I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

FR
Lung Cancer PatientAge: 71

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."

UM
Pancreatic Cancer PatientAge: 48

Osimertinib + BLU-945 for Non-Small Cell Lung Cancer

Los Angeles, California
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

190 Participants Needed

Immunotherapy + Chemotherapy for Small Cell Lung Cancer

Los Angeles, California
This trial tests a new combination of immunotherapy and chemotherapy for patients with advanced lung cancer. The treatment uses two drugs to help the immune system fight cancer, along with standard chemotherapy to kill cancer cells. Researchers hope this new approach will improve survival compared to existing treatments.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

460 Participants Needed

BI 764532 for Small Cell Lung Cancer

Los Angeles, California
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find a suitable dose of BI 764532 that people with advanced cancer can tolerate. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. The study has 2 parts. In Part 1, participants are put into 2 groups randomly, which means by chance. Participants have an equal chance of being in either group. One group gets dose 1 of BI 764532 and the other group gets dose 2 of BI 764532. In Part 2, all participants receive the same dose of BI 764532. Part 2 is open to people with a certain kind of tumour called extrapulmonary neuroendocrine carcinoma. All participants receive BI 764532 as an infusion into a vein when starting treatment. If there is benefit for the participants and if they can tolerate it, the treatment is given up to the maximum duration of the study. During this time, participants visit the study site regularly. The total number of visits depends on how they respond to and tolerate the treatment. The first study visits include an overnight stay to monitor participants´ safety. Doctors record any unwanted effects and regularly check the general health of the participants.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

174 Participants Needed

HPN328 + Atezolizumab for Small Cell Lung Cancer

Los Angeles, California
This trial is testing a new drug, HPN328, alone and with another drug, Atezolizumab, in patients with advanced cancers that have a specific protein called DLL3. The goal is to see if these treatments can help the immune system find and destroy cancer cells. This is aimed at patients whose cancers are hard to treat with standard therapies.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

232 Participants Needed

Immunotherapy for Cancer

Los Angeles, California
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

1609 Participants Needed

PARG Inhibitor for Advanced Cancers

Los Angeles, California
This trial is testing a new drug called IDE161 to see if it is safe and effective for patients with advanced cancers that have specific genetic changes. The drug works by preventing cancer cells from repairing their DNA, which can lead to their death.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

216 Participants Needed

RYZ101 + Standard Treatments for Small Cell Lung Cancer

Los Angeles, California
This trial is testing a new drug, RYZ101, combined with standard cancer treatments in patients with a specific type of untreated lung cancer. The new drug aims to target certain receptors on cancer cells, while the other drugs work to kill the cancer cells and help the immune system fight them.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

49 Participants Needed

Atezolizumab + Radiation Therapy for Lung Cancer

Beverly Hills, California
This phase III trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving atezolizumab and radiation therapy may work better than radiation therapy alone in treating patients with early non-small cell lung cancer.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

480 Participants Needed

Durvalumab + Chemoradiation for Non-Small Cell Lung Cancer

Burbank, California
This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to see if adding durvalumab to standard chemoradiation followed by additional durvalumab can extend patients life and/or prevent the tumor from coming back compared to the usual approach of chemoradiation alone followed by durvalumab.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

660 Participants Needed

Dato-DXd + Rilvegostomig for Non-Small Cell Lung Cancer

Beverly Hills, California
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

675 Participants Needed

123456

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Lung Cancer clinical trials in Ventura, CA pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Lung Cancer clinical trials in Ventura, CA work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Lung Cancer trials in Ventura, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Ventura, CA for Lung Cancer is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Ventura, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Lung Cancer medical study in Ventura, CA?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Lung Cancer clinical trials in Ventura, CA?

Most recently, we added Zongertinib for Lung Cancer, Niraparib + Temozolomide for Small Cell Lung Cancer and WSD0922-FU for Lung Cancer to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in California

Anxiety Clinical Trials in California

Schizophrenia Clinical Trials in California

ADHD Clinical Trials in California

Bipolar Disorder Clinical Trials in California

Multiple Sclerosis Clinical Trials in California

Autism Clinical Trials in California

Treatment Resistant Depression Clinical Trials in California

Borderline Personality Disorder Clinical Trials in California

Social Anxiety Disorder Clinical Trials in California

Parkinson's Disease Clinical Trials in California

Alzheimer's Disease Clinical Trials in California

By Location

Clinical Trials near Los Angeles, CA

Clinical Trials near San Francisco, CA

Clinical Trials near San Diego, CA

Clinical Trials near Sacramento, CA

Clinical Trials near La Jolla, CA

Clinical Trials near Orange, CA

Clinical Trials near Stanford, CA

Clinical Trials near Palo Alto, CA

Clinical Trials near Long Beach, CA

Clinical Trials near Duarte, CA

Clinical Trials near Oakland, CA

Clinical Trials near Torrance, CA

Other People Viewed

By Subject

Top Colorectal Cancer Clinical Trials near Ventura, CA

Top Breast Cancer Clinical Trials near Ventura, CA

Top Clinical Trials near Ventura, CA

145 Prostate Cancer Trials near Ventura, CA

Top Depression Clinical Trials near Ventura, CA

Top Lung Cancer Clinical Trials near Anaheim, CA

207 Clinical Trials near Ventura, CA

Top Lung Cancer Clinical Trials near San Diego, CA

Top Lung Cancer Clinical Trials near Chicago, IL

Top Lung Cancer Clinical Trials near Miami, FL

Top Lung Cancer Clinical Trials near Raleigh, NC

Top Lung Clinical Trials

By Trial

Serplulimab + Chemotherapy for Small Cell Lung Cancer

Pembrolizumab + Chemotherapy for Non-Small Cell Lung Cancer

Trametinib + Pembrolizumab for Lung Cancer

Pre-Surgical Respiratory Muscle Training for Lung Cancer

18F-C-SNAT4 for Lung Cancer

Pembrolizumab for Lung Cancer

Chemotherapy + High-Dose Radiation for Lung Cancer

Stereotactic Radiotherapy for Lung Cancer

CivaSheet for Lung Cancer

Precision Radiotherapy for Non-Small Cell Lung Cancer

Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

Osimertinib + Surgery + Radiation for Lung Cancer

Related Searches

Top Tinnitus Clinical Trials near Tampa, FL

Top Weight-loss Clinical Trials near Albuquerque, NM

Top Weight-loss Clinical Trials near Ventura, CA

Atezolizumab + Bevacizumab for Melanoma

PCSK9 + PD-1 Inhibitors for Non-Small Cell Lung Cancer

Wake Training + TMR for Sleep Apnea

Embolization for Rotator Cuff Injury

In-home Chemotherapy for Bladder Cancer

Ketamine for Endometriosis Pain

Feedback to Reduce Antibiotic Use for Respiratory Infections

Piano Training for Stroke

Nicotine for Depression

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial